
Evolus EOLS
$ 4.21
-1.86%
Annual report 2025
added 03-03-2026
Evolus EV - Enterprise Value 2011-2026 | EOLS
Annual EV - Enterprise Value Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 467 M | 1.03 B | 985 M | 601 M | 399 M | 408 M | 335 M | 375 M | 228 M | 84.6 M | 69.3 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 69.3 M | 453 M |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
23.6 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.07 | -0.47 % | $ 115 M | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Harrow Health
HROW
|
2.21 B | $ 38.95 | -27.32 % | $ 1.43 B | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.62 | -0.57 % | $ 1.36 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
91.9 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
11.1 M | $ 0.55 | -0.97 % | $ 9.61 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 4.5 | -7.02 % | $ 63.3 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
-110 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.52 | -5.26 % | $ 86.3 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.86 | -4.67 % | $ 377 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.87 | -1.33 % | $ 454 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
141 M | $ 11.92 | 1.24 % | $ 847 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
57.3 M | $ 0.9 | 0.37 % | $ 21 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.77 | -3.11 % | $ 2.11 B | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.38 | -3.17 % | $ 402 M | ||
|
Perrigo Company plc
PRGO
|
7.03 B | $ 11.38 | -7.97 % | $ 1.58 B | ||
|
Sundial Growers
SNDL
|
-2.47 M | $ 1.53 | 0.33 % | $ 3.37 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 22.06 | 3.67 % | $ 1.02 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
170 M | $ 4.67 | -3.51 % | $ 141 M | ||
|
SCYNEXIS
SCYX
|
91.7 M | $ 0.73 | -2.19 % | $ 34.9 M | ||
|
Solid Biosciences
SLDB
|
197 M | $ 5.99 | -3.47 % | $ 244 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.76 | -2.66 % | $ 3.43 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
33.6 M | $ 2.26 | 1.0 % | $ 23.6 M | ||
|
Tilray
TLRY
|
1.96 B | $ 7.37 | -2.97 % | $ 4.55 B | ||
|
Veru
VERU
|
111 M | $ 2.54 | -3.05 % | $ 343 M | ||
|
Viatris
VTRS
|
41.3 B | $ 15.09 | -3.89 % | $ 18.1 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.79 | -2.48 % | $ 3.41 M |